search
Back to results

Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition

Primary Purpose

Healthy

Status
Completed
Phase
Phase 1
Locations
India
Study Type
Interventional
Intervention
Montelukast sodium
Sponsored by
Dr. Reddy's Laboratories Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy focused on measuring Bioequivalence, Montelukast Sodium, crossover

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Subjects must fulfill the following criteria to be considered for inclusion into this study.

  • Healthy subjects within the age range of 18 to 50 years.
  • A body mass index between 18.5 to 24.9 Kg/m2
  • Given written informed consent to participate in the study.
  • Absence of disease markers of HIV 1 & 2, hepatitis B & C virus and RPR.
  • Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening.
  • A normal 12-lead ECG.
  • A normal chest X-ray (PA view).
  • Compliance with the requirement of the entire protocol.
  • No history or no evidence of hypersensitivity to Montelukast and to any component of the formulation.
  • No history of gastrointestinal problems (ulcers).
  • No history of significant systemic diseases.
  • No history of psychiatric disorders.
  • No history of allergic rash.
  • No history of addiction to any recreational drug or drug dependence.
  • No donation of blood (one unit or 350 mL) within 90 days prior to study check in.
  • No Participation in any clinical study within the past 90 days.
  • No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in.
  • No history of dehydration from dialThea, vomiting or any other reason within a period of24.0 hours prior to study check-in.
  • No family history of neurological disorders. Not consumed alcohol and xanthine containing food and beverages (chocolates, tea, coffee or cola drink:s), cigarettes and tobacco products, for at least 48.0 hours prior to study check-in.
  • Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Ca1U1abinoids and Barbiturates) in urine during the day of study check-in.
  • Not consumed grapefruit (mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in.
  • Negative alcohol breath analysis during the study check-in.
  • Female volunteers demonstrating a negative pregnancy test.
  • If study volunteer is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence.

or is postmenopausal for at least 1 year. or is surgically . sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the study volunteer).

Exclusion Criteria The subjects were excluded based on the following criteria.

  • History of seizures.
  • Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study.
  • History of alcohol consumption for more than two units/day (1 unit = 30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48 hours prior to check-in.
  • High caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/beedies/cigars per day) consumption.
  • History of difficulty with donating blood or difficulty in accessibility of veins.
  • An unusual or abnormal diet, for whatever reason e.g. because of fasting due to religious reasons.

Sites / Locations

  • AXIS Clinicals Limited,

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Montelukast Sodium Oral Granules

SINGULAIR

Arm Description

Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited

(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA

Outcomes

Primary Outcome Measures

Area under curve(AUC)

Secondary Outcome Measures

Full Information

First Posted
September 20, 2012
Last Updated
September 20, 2012
Sponsor
Dr. Reddy's Laboratories Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01691469
Brief Title
Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition
Official Title
An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2012
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
January 2011 (Actual)
Study Completion Date
February 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Reddy's Laboratories Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is an open label, randomised, balanced, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study.
Detailed Description
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose, crossover, oral bioequivalence study of Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited, India comparing with that of SINGULAIR® (Montelukast sodium) 4mg oral granules of Merck Sharp & Dohme Ltd., USA in healthy, adult, human subjects under fed conditions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
Bioequivalence, Montelukast Sodium, crossover

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
31 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Montelukast Sodium Oral Granules
Arm Type
Experimental
Arm Description
Montelukast Sodium Oral Granules 4mg of Dr. Reddy's Laboratories Limited
Arm Title
SINGULAIR
Arm Type
Active Comparator
Arm Description
(Montelukast sodium) Oral Granules 4mg of Merck Sharp & Dohme Ltd., USA
Intervention Type
Drug
Intervention Name(s)
Montelukast sodium
Other Intervention Name(s)
SINGULAIR
Intervention Description
Montelukast Sodium Oral Granules 4mg
Primary Outcome Measure Information:
Title
Area under curve(AUC)
Time Frame
Pre-dose (0.00) and 0.50, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.00, 7.50, 8.00, 8.50, 9.00, 12.00, 16.00, 20.00 and 24.00 hours post dose.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects must fulfill the following criteria to be considered for inclusion into this study. Healthy subjects within the age range of 18 to 50 years. A body mass index between 18.5 to 24.9 Kg/m2 Given written informed consent to participate in the study. Absence of disease markers of HIV 1 & 2, hepatitis B & C virus and RPR. Absence of significant disease or clinically significant abnormal laboratory values on laboratory evaluation, medical history and physical examination during the screening. A normal 12-lead ECG. A normal chest X-ray (PA view). Compliance with the requirement of the entire protocol. No history or no evidence of hypersensitivity to Montelukast and to any component of the formulation. No history of gastrointestinal problems (ulcers). No history of significant systemic diseases. No history of psychiatric disorders. No history of allergic rash. No history of addiction to any recreational drug or drug dependence. No donation of blood (one unit or 350 mL) within 90 days prior to study check in. No Participation in any clinical study within the past 90 days. No receipt of any prescription drugs or over-the-counter drugs (e.g.: Cold preparations, and antacid preparations vitamins and natural products used for therapeutic benefits), within two weeks prior to study check-in. No history of dehydration from dialThea, vomiting or any other reason within a period of24.0 hours prior to study check-in. No family history of neurological disorders. Not consumed alcohol and xanthine containing food and beverages (chocolates, tea, coffee or cola drink:s), cigarettes and tobacco products, for at least 48.0 hours prior to study check-in. Negative results for drugs of abuse (Benzodiazepines, Cocaines, Opioids, Amphetamines, Ca1U1abinoids and Barbiturates) in urine during the day of study check-in. Not consumed grapefruit (mosumbi/sweet lime) juice within the 48.0 hours prior to study check-in. Negative alcohol breath analysis during the study check-in. Female volunteers demonstrating a negative pregnancy test. If study volunteer is a female volunteer and is of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as condoms, foams, jellies, diaphragm, intrauterine device (IUD), or abstinence. or is postmenopausal for at least 1 year. or is surgically . sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy has been performed on the study volunteer). Exclusion Criteria The subjects were excluded based on the following criteria. History of seizures. Received pharmacological agents known to significantly induce or inhibit drug metabolizing enzymes within 14 days of the start of the study. History of alcohol consumption for more than two units/day (1 unit = 30 mL of spirit/or 1 pint of beer), or having consumed alcohol within 48 hours prior to check-in. High caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/beedies/cigars per day) consumption. History of difficulty with donating blood or difficulty in accessibility of veins. An unusual or abnormal diet, for whatever reason e.g. because of fasting due to religious reasons.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
A. Jayachandra Reddy, Dr.
Organizational Affiliation
Axis Clinicals Limited
Official's Role
Principal Investigator
Facility Information:
Facility Name
AXIS Clinicals Limited,
City
Hyderabad
State/Province
Andhra Pradesh
ZIP/Postal Code
500 049
Country
India

12. IPD Sharing Statement

Learn more about this trial

Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition

We'll reach out to this number within 24 hrs